אקספוביו 40 מ"ג - Xpovio 40 mg
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | L01XX Other antineoplastic agents | |||||||||||||
| ×ר××× ×¤×¢×× (ATC5) | Â
| |||||||||||||
| צ×רת ××ª× | פ××× - PER OS | |||||||||||||
| צ×רת ××× ×× | ×××××, TABLETS ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | |||||||||||||
| ×ת×××× | Xpovio® is indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. | |||||||||||||
| ||||||||||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
 ××× ×¢××× ×ר××¤× Â | |||||||||||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ×קספ×××× 40 ×"× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | KARYOPHARM THERAPEUTICS INC., USA |
| ×©× ××¢× ×ר×ש×× | PROMEDICO LTD |
| ר×ש××× | ת×ר×× ××ש×: 9/2023. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | 04/12/2024 |
השינוי האחרון נעשה בֹ־4 בדצמבר 2024 ב־12:22